Clinical trials: Localized Prostate Cancer
Prostate Cancer
PROFIT - Prostate Fractionated Irradiation Trial
This trial is designed to determine whether an 8-week course of escalated dose conformal radiation can be compressed safely, and with similar efficacy into a 4-week course.
- Trial name
- NCT00304759
- Testing
- 7800 cGy/39 fractions in 8 weeks, 6000 cGy/20 fractions in 4 weeks
- Where
- 25 sites in Australia, Canada and 1 more
- Volunteers
- 1,204 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.
- Trial name
- NCT00052481
- Testing
- quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Shorter Radiation Schedule for the Treatment of Prostate Cancer
To improve the management of patients with early stage prostate cancer.
- Trial name
- NCT00201916
- Testing
- 5250 cGy/20 fractions over 28 days, 6600 cGy/33 fractions over 45 days
- Where
- 16 sites in Canada
- Volunteers
- 936 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
- Trial name
- NCT00329043
- Testing
- LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer of the Prostate
The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects
The aim of this study is: To investigate which sexual side effects occur after external beam radiation therapy and brachie therapy To investigate how many patients are affected To investigate if there is a time dependency for the…
- Trial name
- NCT02274350
- Testing
- radiation therapy
- Volunteers
- 515 people
- Sponsor
- Herlev Hospital
Prostate Cancer
The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife
Giving a higher dose of radiation to the dominant tumour nodule within the prostate is hypothesized to improve tumour control. This trial will assess whether this technique, delivered in 5 treatments, can be delivered without…
- Trial name
- SPARC (NCT02145494)
- Testing
- Radiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer
The purpose of this study is to assess quality-of-life of men with prostate cancer. "Quality-of-life" means how you feel about your life as a result of your disease and its treatment.
- Trial name
- NCT00582842
- Testing
- Interview, survey instruments using Web-Based Data Collection System (WBDC) survey content
- Where
- 5 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance.
- Trial name
- NCT02326805
- Testing
- Laboratory Biomarker Analysis, Rilimogene Galvacirepvec
- Where
- 7 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.
Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent in the treatment of localized prostate cancer.
- Trial name
- GCP (NCT00584532)
- Testing
- GCP - Genistein Combined Polysaccharide
- Volunteers
- 66 people
- Sponsor
- University of California, Davis